Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
23.91
+0.21 (0.89%)
May 13, 2025, 3:59 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
$672,658
Profits / Employee
$105,470
Market Cap
44.41B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Daiichi Sankyo Company News
- 6 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - Benzinga
- 7 days ago - ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial - Benzinga
- 16 days ago - Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO - CNBC
- 18 days ago - Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Daiichi Sankyo rises on share buyback plan - Seeking Alpha
- 18 days ago - Daiichi Sankyo repors FY results - Seeking Alpha
- 23 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 4 weeks ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha